Evidence map›Paper›PMID 33653320›Full record

Trial reportBMC oral health2021

Efficacy of serratiopeptidase after impacted third molar surgery: a randomized controlled clinical trial.

Zaid Tamimi, Rola Al Habashneh, Islam Hamad, Mutasim Al-Ghazawi, Ala' Abu Roqa'a, Hamza Kharashgeh

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC oral health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02493179 (Efficacy Evaluation of the Dose Regimen of Serratiopeptidase), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02493179 phase4unknown statusnot on this map

Efficacy Evaluation of the Dose Regimen of Serratiopeptidase (Serodase 5 mg Tablet) in the Treatment of Inflammation After Third Molar Surgery

TypeinterventionalSponsorHayat Pharmaceutical Co. PLCRan2015 to 2016Enrolled112ConditionsTrismus, Swelling, InflammationArmsSerodase 5 mg, Placebo
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. The biotechnological potential of proteases from hematophagous arthropod vectors.Frontiers in cellular and infection microbiology · 2023
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Zaid TamimiDepartment Oral Surgery and Oral Medicine, Jordan University of Science and Technology, Irbid, Jordan. zztamimi@just.edu.jo.ORCID 0000-0001-7972-0331
Rola Al HabashnehDepartment Periodontology, Jordan University of Science and Technology, Irbid, Jordan.
Islam HamadDepartment of Pharmacy, American University of Madaba, Amman, Jordan.
Mutasim Al-GhazawiDepartment of Biopharmaceutics and Clinical Pharmacy, The University of Jordan, Amman, Jordan.
Ala' Abu Roqa'aThe First for Research and Development LLC, Amman, Jordan.
Hamza KharashgehDepartment Oral Surgery and Oral Medicine, Jordan University of Science and Technology, Irbid, Jordan.
Jordan University of Science and Technology · JOAmerican University of Madaba · JOUniversity of Jordan · JO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSerratiopeptidase has been clinically used in controlling surgical and non-surgical inflammatory conditions. This study was conducted to assess the therapeutic effect of Serratiopeptidase in patients undergoing surgical removal of impacted mandibular third molar.

methodsThis randomized clinical trial investigated the efficacy of Serratiopeptidase and Paracetamol after surgical removal of impacted third molar for 5 days (n = 67) as compared with an equivalent dose of placebo and Paracetamol (n = 66). Outcome measures were reported pain, trismus and swelling using Laskin method. All outcome measures were recorded on days 0, 1, 2, 4, and 5 post-surgeries.

resultsIn this clinical trail 133 patients (mean age 23 years, 54% female) completed the study. Baseline characteristics were comparable across treatment groups. Serratiopeptidase significantly improved trismus compared with control on the 4

conclusionSerratiopeptidase resulted in better inflammation improvement than placebo over 5 days. Further studies are warranted to assess longer-term and clinical outcomes, as well as safety. CLINICAL RELEVANCE: Serratiopeptidase administered postoperatively helps in improving trismus and swelling after removal of impacted lower third molars. Trial registration The study was registered in ClinicalTrial.gov under the number NCT02493179. Registered 1st of June 2015, https://clinicaltrials.gov/ct2/results?cond=serratiopeptidase .

Indexed as

Molar, ThirdTooth, ImpactedAdultDouble-Blind MethodEdemaFemaleHumansMalePeptide HydrolasesPostoperative PainTooth ExtractionTreatment OutcomeTrismusYoung AdultPeptide HydrolasesserratiopeptidaseInflammationMolarSurgerySwellingThirdTrismus

Identifiers

PMID33653320
PMCPMC7927242
OpenAlexW3135819538

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.